Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets